Table of Content


Table of Contents
1.0 Executive Summary
1.1 Facts and Findings: Neurodegenerative Diseases
1.2 Research Focus: Neurodegenerative Diseases
1.3 Research Scope: Foreseeing Challenges and Solutions
1.4 Analysis Framework: Frost & Sullivan’s Core Value
1.5 Research Methodology
2.0 Technology Landscape and Trends
2.1 Neurodegenerative Diseases: Facts and Challenges
2.2 Neurodegenerative Diseases: Multifactorial Onset
2.3 Neurodegenerative Diseases: Concurrent Triggering Factors
2.4 Neurodegenerative Diseases: Emerging Therapies
2.5 Neurodegenerative Diseases: Complementary Therapies
3.0 Emerging Therapies to Address Neurodegeneration
3.1 Therapeutic and Diagnostic Solutions: PROTACs
3.2 Neurodegenerative Therapies: Targeting Protein Ligands
3.3 Therapeutic and Diagnostic Solutions: Peptoids
3.4 Neurodegenerative Therapies: Five Peptoid Approaches
3.5 Neurodegenerative Therapies: Aggregation Inhibitors
3.6 Neurodegenerative Therapies: Cell Signaling Modulators
3.7 Neurodegenerative Therapies: Biomimetic Neuroprotectors
3.8 Neurodegenerative Therapies: Inflammation Regulators
3.9 Neurodegenerative Therapies: Imaging Diagnostics Biomarkers
3.10 Neurodegenerative Therapies: Summary of Peptoid Interventions
3.11 Therapeutic and Diagnostic Solutions: Stem Cell/Gene Therapies
3.12 Neurodegenerative Therapies: Cell Therapy Developments
3.13 Therapeutic and Diagnostic Solutions: Gut Microbiome
3.14 Neurodegenerative Therapies: Gut Microbiome Interventions
3.15 Therapeutic and Diagnostic Solutions: Nanotech, Prodrug, and Codrug
3.16 Therapeutic and Diagnostic Solutions: Cannabidiols
3.17 Neurodegenerative Therapies: Prevention and Management
4.0 Technology Status Review and Assessment
4.1 Neurodegenerative Preclinical Models: Needs and Complexities
4.2 Neurodegenerative Models’ Pitfalls: Alzheimer’s Disease
4.3 Neurodegenerative Models’ Pitfalls: Parkinson’s Disease
4.4 Present Status of Therapeutics Technology
4.5 Alzheimer’s Disease Drug Development Status
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.6 Parkinson’s Disease Drug Development Status
5.0 Technology Radar Intelligent Solutions
5.1 From Palliative Treatment to Future Strategies
5.2 New Treatment Strategies and Preliminary Outcomes
5.2 New Treatment Strategies and Preliminary Outcomes (continued)
5.3 Monoclonal Antibodies Advancing Clinical Trials
5.4 Pharmacological Agents Enhancing Autophagy
5.5 Top Promising Candidates for Alzheimer’s Disease
5.6 Parkinson’s Disease Top Companies
6.0 Market Potential and Technology Adoption
6.1 Neurodegenerative Diseases Market Potential
6.2 Overall Environmental Impact Factors
6.3 Best-fit Industry Partnerships: SWOT Analysis
6.4 Collaborative Framework for Neurodegenerative Diseases
6.5 Overview of Business Partnerships and Technology Capabilities
6.6 Key Aspects to Target through Collaborative Initiatives
7.0 Business Landscape and Intellectual Property Analysis
7.1 Actionable Impact on Business Development
7.2 Repercussions on Businesses and Processes
7.3 Technology Transfer Assessment
8.0 Appendix
8.1 Alzheimer’s Disease Drug Pipeline
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.2 Parkinson’s Disease Drug Pipeline
8.2 Parkinson’s Disease Drug Pipeline (continued)
9.0 Key Industry Contacts
9.1 Key Industry Influencers
9.1 Key Industry Influencers (continued)
9.1 Key Industry Influencers (continued)
9.1 Key Industry Influencers (continued)
9.1 Key Industry Influencers (continued)
Legal Disclaimer